Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was up 37.9% on Thursday . The stock traded as high as C$0.24 and last traded at C$0.20. Approximately 640,100 shares changed hands during mid-day trading, an increase of 45% from the average daily volume of 440,650 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The firm has a market capitalization of C$16.12 million, a PE ratio of -9.25 and a beta of 0.20. The stock’s 50-day simple moving average is C$0.09 and its 200-day simple moving average is C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Investing in Construction Stocks
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Canada Bond Market Holiday: How to Invest and Trade
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Investing In Preferred Stock vs. Common Stock
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
